iTeos Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| iTeos Therapeutics, Inc. | ITOS - NASDAQ |
$16.00-$18.00 | $19.00 | $25.55 | 10.6 million | 7/24/2020 |
| JP Morgan, SVB Leerink, Piper Sandler | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-06-24 Terms Added 2020-07-20 | ||||||
iTeos Therapeutics, Inc. Quote & Chart - Click for current quote - ITOS
IPO Boutique aggregates information on public companies and private companies, such as "ITOS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About iTeos Therapeutics, Inc. (adapted from iTeos Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ITOS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.